Impact of modifiable lifestyle factors on outcomes after breast cancer diagnosis: the Setouchi Breast Cancer Cohort Study.
Impact of modifiable lifestyle factors on outcomes after breast cancer diagnosis: the Setouchi Breast Cancer Cohort Study.
复制标题
可改变的生活方式因素对乳腺癌诊断后结果的影响：濑户内乳腺癌队列研究。
DOI：
10.1093/jjco/hyv033
复制
发表时间：
2015
期刊：
影响因子：
2.4
通讯作者：
Doihara H; Executive Committee for the Setouchi Breast Cancer Cohort Study.
中科院分区：
文献类型：
--
作者：
Taira N;Akiyama I;Ishihara S;Ishibe Y;Kawasaki K;Saito M;Shien T;Nomura T;Hara F;Mizoo T;Mizota Y;Yamamoto S;Ohsumi S;Doihara H; Executive Committee for the Setouchi Breast Cancer Cohort Study.
这项大型队列研究的主要目的是调查乳腺癌诊断后可改变的生活方式因素对乳腺癌预后的影响。这些因素包括体力活动、吸烟、饮酒、诊断后肥胖和体重增加、替代药物和饮食因素。诊断为0至III期乳腺癌的妇女有资格参加本研究。生活方式、替代药物的使用、社会心理因素、生殖因素和健康相关生活质量将在乳腺癌诊断时（基线）以及诊断后1、2、3和5年通过问卷进行评估。临床信息和乳腺癌结果将从乳腺癌数据库获得。主要终点将是无病生存期。次要终点是总生存率、健康相关生活质量、乳腺癌相关症状和不良事件。患者招募于2013年2月开始。计划在5年的招募期内招募2000名乳腺癌患者。本文阐述了本研究的概念。
The primary purpose of this large cohort study is to investigate the effects on breast cancer outcomes of modifiable lifestyle factors after breast cancer diagnosis. These factors include physical activity, smoking, alcohol consumption, obesity and weight gain after diagnosis, alternative medicine and dietary factors. Women diagnosed with Stage 0 to III breast cancer are eligible for participation to this study. Lifestyle, use of alternative medicine, psychosocial factors, reproductive factors and health-related quality of life will be assessed using a questionnaire at the time of breast cancer diagnosis (baseline), and 1, 2, 3 and 5 years after diagnosis. Clinical information and breast cancer outcomes will be obtained from a breast cancer database. The primary endpoint will be disease-free survival. Secondary endpoints are overall survival, health-related quality of life, breast cancer-related symptoms and adverse events. Patient recruitment commenced in February 2013. Enrollment of 2000 breast cancer patients is planned during the 5-year recruitment period. The concept of the study is described in this article.